Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?

Comparing SG&A Cost Management: Sanofi vs. Jazz Pharmaceuticals

__timestampJazz Pharmaceuticals plcSanofi
Wednesday, January 1, 20144061140008565000000
Thursday, January 1, 20154491190009496000000
Friday, January 1, 20165028920009592000000
Sunday, January 1, 201754415600010164000000
Monday, January 1, 20186835300009934000000
Tuesday, January 1, 20197369420009883000000
Wednesday, January 1, 20208542330009390000000
Friday, January 1, 202114516830009555000000
Saturday, January 1, 2022141696700010539000000
Sunday, January 1, 2023134310500010765000000
Monday, January 1, 20249183000000
Loading chart...

Data in motion

A Tale of Two Pharmaceutical Giants: SG&A Cost Management

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Sanofi and Jazz Pharmaceuticals plc have shown distinct approaches to handling these costs. Sanofi, a global leader, consistently reported higher SG&A expenses, averaging around $9.8 billion annually. In contrast, Jazz Pharmaceuticals, a smaller player, maintained an average of $839 million, reflecting a more conservative approach.

Despite Sanofi's larger scale, Jazz Pharmaceuticals demonstrated a significant increase in SG&A expenses, peaking at $1.45 billion in 2021, a 258% rise from 2014. Meanwhile, Sanofi's expenses grew by only 26% over the same period. This data highlights the strategic differences in cost management between these two companies, offering insights into their operational efficiencies and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025